SM
SIOX

Sabby Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Sabby Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-231
Closed -$974K – 197
2017
Q4 		$974K Sell
231
-729
-76% -$32.7K 0.09% 72
2017
Q3 		$5.28M Buy
960
+494
+106% +$83.3K 0.35% 37
2017
Q2 		$8.64M Buy
466
+11
+2% +$1.93K 0.57% 27
2017
Q1 		$5.44M Buy
455
+125
+38% +$13.1K 0.29% 46
2016
Q4 		$3.28M Buy
+330
New +$34.8K 0.19% 73

Other funds holding SIOX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sabby Management's SIOX Position: Q4 2018 in Review

Sabby Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 16,909 shares — an estimated $327K sold.

Sabby Management first reported a position in SIOX in Q3 2015 and held it in 10 quarters. The position peaked at $4.42M in Q3 2017. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

  • Sabby Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Sabby Management sold 16,909 Sio Gene Therapies Inc. Common Stock shares in Q4 2018, an estimated $327K.
  • Sabby Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 10 quarters.
  • Sabby Management's Sio Gene Therapies Inc. Common Stock position peaked at $4.42M in Q3 2017.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.